Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
busulfan + etoposide + cytarabine + melphalan
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Busulfan + etoposide + cytarabine + melphalan (BuEAM) is a high-dose combination chemotherapy regimen used primarily as a conditioning treatment before autologous stem cell transplantation (ASCT), especially in patients with lymphomas such as non-Hodgkin lymphoma and peripheral T-cell lymphomas. The regimen replaces carmustine in the standard BEAM protocol with intravenous busulfan. Each component has a distinct mechanism of action: - Busulfan is an alkylating agent that crosslinks DNA, leading to cell death. - Etoposide inhibits topoisomerase II, causing DNA strand breaks. - Cytarabine is an antimetabolite that inhibits DNA synthesis by acting as a cytidine analog. - Melphalan is another alkylating agent that crosslinks DNA and RNA. The combination aims to maximize myeloablation and anti-tumor activity prior to stem cell rescue. Clinical studies have shown BuEAM to be effective and generally well tolerated for ASCT conditioning in various lymphoma subtypes[1][2][8].
- Other names
- BuEAMbusulfan-etoposide-cytarabine-melphalan regimen
02
Targets
TOP2A (DNA topoisomerase II)DNA polymerase familyDNA
Beyond the preview
Go deeper on busulfan + etoposide + cytarabine + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on busulfan + etoposide + cytarabine + melphalan.